Charles Schwab’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Charles Schwab’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-343,731	Closed	-$18.5M	–	3085
2017 Q4	$18.5M	Buy	343,731 +27,800	+9%	+$1.52M	0.01%	1036
2017 Q3	$18M	Sell	315,931 -100,881	-24%	-$5.91M	0.02%	1007
2017 Q2	$25.1M	Buy	416,812 +3,739	+0.9%	+$213K	0.02%	705
2017 Q1	$22.5M	Buy	+413,073	New	+$20.3M	0.02%	753

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Charles Schwab's BIVV Position: Q1 2018 in Review

Charles Schwab sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 343,731 shares — an estimated $18.5M sold.

Charles Schwab first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $25.1M in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Charles Schwab reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Charles Schwab sold 343,731 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $18.5M.
Charles Schwab first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Charles Schwab's Bioverativ Inc. Common Stock position peaked at $25.1M in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Charles Schwab's 13F filing for Q1 2018, filed 7 May 2018.